Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...
There's robust potential in US tech, pharma and Qantas, while red flags exist in a number of ASX companies that make them ...
Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.
Eli Lilly slashes the revenue guidance for the fourth quarter and fiscal 2024 but offers a bullish outlook for 2025.
Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE: NVO) following recent ...
Artificial intelligence requires enormous computing power, pushing demand for specialized data centers that enable technology ...
The FTSE 100 ( ^FTSE) and European stocks gained on Wednesday as traders digested news that UK inflation unexpectedly fell to ...
Hosted on MSN7h
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays BullishEli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst ...
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...
Shares rose 3.6% in premarket trading. Citi, one of the nation’s largest banks, has been pursuing a turnaround strategy under CEO Jane Fraser, who has sold off some business and reorganized the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback